Are GLP-1s everything we hoped for?
US$ 29.94
glp-1 receptor agonists in idiopathic intracranial hypertension Use of glucagon-like peptide-1 : a systematic review | The Journal of Headache and Pain glp 1 and intracranial hypertension
Description
Diabetes Obes Metab 2010
Preclinical models have suggested a potential biological pathway through which GLP-1RAs could increase PDAC risk
Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, et al
Regulators are responding to this expansion with increased oversight
Despite the increasing prevalence of obesity worldwide, effective long-term treatments remain a challenge [2]
However, it acts in contrast with GLP-1 as much as glucagon release is concerned by enhancing its release
